Flexion Therapeutics

208 articles about Flexion Therapeutics

• Flexion Therapeutics Announces Proposed Public Offering of Common Stock

  5/20/2020

  Flexion Therapeutics, Inc. (Nasdaq:FLXN) today announced that it has commenced an underwritten public offering of $75,000,000 of shares of its common stock. Flexion also expects to grant the underwriters a 30-day option to purchase up to an additional 15% of the shares of common stock offered in the public offering. All of the shares in the offering will be sold by Flexion.

• Flexion Therapeutics to Present at the RBC Capital Markets 2020 Virtual Global Healthcare Conference

  5/13/2020

  Flexion Therapeutics, Inc. announced that Michael Clayman, M.D., President and Chief Executive Officer, will participate in an analyst-led fireside chat at the RBC Capital Markets 2020 Virtual Global Healthcare Conference.

• Flexion Therapeutics Reports First-Quarter 2020 Financial Results and Recent Business Highlights

  5/7/2020

  Company reported ZILRETTA® (triamcinolone acetonide extended-release injectable suspension) net sales of $20.1 million in first quarter 2020

• Flexion Therapeutics Announces Virtual Poster Presentations for FX201, an Intra-Articular Gene Therapy Candidate for the Treatment of Osteoarthritis, at the American Society of Gene & Cell Therapy Annual Meeting

  5/5/2020

  FX201 preclinical in vivo data in a rodent model of OA showed slowing of disease progression 12 weeks post-surgery, persistence of the vector genome in the joint for at least 92 days with absence of systemic distribution, and a favorable safety profile Productivity, purification yields, and product quality from FX201 manufacturing studies demonstrate capable manufacturing process to support FX201 clinical trials BURLINGTON, Mass., May 05, 2020 (GLOBE NEWSWIRE) -- Flexion Therapeutics, I

• 

  Clinical Catch-Up: April 27-May 1

  5/4/2020

  There’s plenty of news related to clinical trials related to COVID-19, but it does seem to be drowning out non-COVID-19-related clinical trials. Here’s a look.

• Flexion Therapeutics Announces Publication of New Abstracts Accepted at Osteoarthritis Research Society International OARSI 2020

  5/1/2020

  Flexion Therapeutics, Inc. (Nasdaq:FLXN) today announced the publication of data from two new analyses of patients treated with ZILRETTA (triamcinolone acetonide injectable suspension), including an analysis of 305 patients in the Phase 3 and Phase 3b trials that showed treatment with ZILRETTA resulted in no deleterious impact on joint structure.

• Flexion Therapeutics to Report First-Quarter 2020 Financial Results on May 7, 2020

  4/30/2020

  Flexion Therapeutics, Inc. (Nasdaq:FLXN) today announced that it will report its first-quarter 2020 financial results after the close of the U.S. financial markets on Thursday, May 7, 2020.

• Flexion Therapeutics Announces Positive Preclinical Data Supporting Development of FX301, a Locally Administered Nav1.7 Inhibitor Product Candidate for Post-Operative Pain

  4/27/2020

  New animal data show FX301 provided sustained, post-operative analgesic effect with no impairment in motor function compared to liposomal bupivacaine and placebo High local concentrations of funapide, the active ingredient in FX301, were measured at the site of administration for the duration of the study, consistent with the creation of a depot providing controlled drug release Electronic poster presentation now available on the American Society of Regional Anesthesia and Acute Pain Me

• Flexion Therapeutics to Present at the 19th Annual Needham Virtual Healthcare Conference

  4/7/2020

  Flexion Therapeutics, Inc. (Nasdaq:FLXN) announced today that Michael Clayman, M.D., President and Chief Executive Officer, will participate in an analyst-led fireside chat at the 19th Annual Needham Virtual Healthcare Conference

• Flexion Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - April 03, 2020

  4/3/2020

  Flexion Therapeutics, Inc. announced equity inducement grants to seven new employees consisting of 9,265 restricted stock units.

• Flexion Therapeutics Announces ZILRETTA® License Agreement and Provides Business Update Amid Coronavirus Pandemic

  4/1/2020

  Company signs exclusive license agreement with Hong Kong Tainuo Pharma Ltd. (HK Tainuo) and Jiangsu Tainuo Pharmaceutical Co. Ltd. (Jiangsu Tainuo) for the development and commercialization of ZILRETTA® in Greater China

• Flexion Therapeutics Reports Fourth-Quarter and Full-Year 2019 Financial Results

  3/12/2020

  Flexion Therapeutics, Inc. (Nasdaq:FLXN) today reported financial results and recent business highlights for the quarter and the full year ended December 31, 2019.

• Flexion Therapeutics Names Melissa Layman Chief Commercial Officer

  3/11/2020

  Flexion Therapeutics, Inc. (Nasdaq:FLXN) today announced that Melissa Layman has been named Chief Commercial Officer (CCO).

• Flexion Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - March 06, 2020

  3/6/2020

  Flexion Therapeutics, Inc. announced equity inducement grants to three new employees consisting of an aggregate of 8,500 stock options and 1,500 restricted stock units.

• Flexion Therapeutics to Report Fourth-Quarter and Full-Year 2019 Financial Results on March 12, 2020

  3/4/2020

  Flexion Therapeutics, Inc. announced that it will report its fourth-quarter and full-year 2019 financial results after the close of the U.S. financial markets on Thursday, March 12, 2020.

• Flexion Therapeutics to Present at the 41st Annual Raymond James Institutional Investors Conference

  2/24/2020

  BURLINGTON, Mass., Feb. 24, 2020 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) announced today that it will be presenting at the 41 st  Annual Raymond James Institutional Investors Conference in Orlando, Florida. Michael Clayman, M.D., President and Chief Executive Officer, is scheduled to present at 11:35 a.m. ET on Monday, March 2, 2020. To access the live webcast and subsequent archived recording of the presentation, please visit the Flexion website at  http://ir.flexionth

• Flexion Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Feb. 07, 2020

  2/7/2020

  Flexion Therapeutics, Inc. announced equity inducement grants to 13 new employees consisting of an aggregate of 40,500 stock options and 6,850 restricted stock units.

• Flexion Therapeutics Announces Preliminary, Unaudited Fourth-Quarter and Full-Year 2019 Revenue and Initial Revenue Guidance for 2020

  1/9/2020

  Flexion Therapeutics, Inc. announced preliminary and unaudited revenue for the fourth-quarter and full-year ended December 31, 2019 and provided initial revenue guidance for 2020.

• Flexion Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Jan. 03, 2020

  1/3/2020

  Flexion Therapeutics, Inc. announced equity inducement grants to five new employees consisting of an aggregate of 17,000 stock options and 2,800 restricted stock units.

• Flexion Therapeutics Announces FDA Approval of sNDA to Revise ZILRETTA® (triamcinolone acetonide extended-release injectable suspension) Product Label

  12/26/2019

  Flexion Therapeutics, Inc. (Nasdaq:FLXN) today announced that the U.S. Food and Drug Administration (FDA) has approved a supplemental New Drug Application (sNDA) to update the product label for ZILRETTA (triamcinolone acetonide extended-release injectable suspension) for the treatment of osteoarthritis (OA) knee pain.